If tirzepatide (Zepbound/Mounjaro) was a leap forward with its dual hormone action, retatrutide is aiming for a triple jump. Eli Lilly's newest weight loss candidate targets not two, but three metabolic hormones—and the first Phase 3 results just dropped.
The numbers are remarkable: 28.7% average weight loss at 68 weeks, equating to about 71 pounds. That's the highest efficacy yet seen in any obesity drug trial.
📋 Development Status: Phase 3 Trials Ongoing
First Phase 3 results (TRIUMPH-4) announced December 2025
7 additional Phase 3 trials expected to report in 2026
Not yet FDA-approved • Estimated approval: 2027
Why "Triple G"?
The nickname comes from the three hormone receptors retatrutide activates:
🧬 The Triple Mechanism
- GLP-1 (Glucagon-like peptide-1): Reduces appetite, slows stomach emptying, improves blood sugar—the same mechanism as Ozempic/Wegovy
- GIP (Glucose-dependent insulinotropic polypeptide): Works synergistically with GLP-1 to enhance satiety and insulin response—shared with tirzepatide
- Glucagon: The new addition—increases energy expenditure and promotes fat burning
The glucagon component is what makes retatrutide unique. While glucagon typically raises blood sugar (it's used to treat severe hypoglycemia), when combined with GLP-1 and GIP agonism, the blood sugar effect is balanced out—and the fat-burning properties remain.
How Does It Compare?
Semaglutide (Wegovy)
Tirzepatide (Zepbound)
Retatrutide
| Drug | Mechanism | Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15% | FDA Approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~21% | FDA Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~29% | Phase 3 |
TRIUMPH-4: The First Phase 3 Results
The TRIUMPH-4 trial, results announced December 2025, studied 445 adults with obesity and knee osteoarthritis. While not a pure weight loss trial (it also measured arthritis pain), it provides our first Phase 3 efficacy data:
| Outcome | 12mg Retatrutide | 9mg Retatrutide | Placebo |
|---|---|---|---|
| Average weight loss | 28.7% (71.2 lbs) | 26.4% | 2.1% |
| ≥25% weight loss | 58.6% | — | — |
| ≥30% weight loss | 39.4% | — | — |
| Knee pain reduction | 75.8% | 62.6% | — |
| Completely pain-free | 12.0% | 14.1% | 4.2% |
The results exceeded Wall Street expectations, which had projected 20-23% weight loss. Lilly's stock crossed $1,000 per share following the announcement.
Beyond Osteoarthritis
The knee pain improvements weren't just from weight loss—1 in 8 patients became completely free of knee pain. This suggests retatrutide could fundamentally change how we treat obesity-related joint disease.
The TRIUMPH Program: What's Coming
TRIUMPH-4 was just the beginning. Seven additional Phase 3 trials are expected to report in 2026:
| Trial | Population | Focus |
|---|---|---|
| TRIUMPH-1 | Obesity (no diabetes) | Pure weight loss (80 weeks) |
| TRIUMPH-2 | Type 2 diabetes | Weight loss + glycemic control |
| TRIUMPH-3 | Sleep apnea | Weight loss + apnea resolution |
| Additional trials | Various | Chronic low back pain, MASH, CV outcomes |
Analysts at Citi predict TRIUMPH-1, which runs for 80 weeks (vs. 68 for TRIUMPH-4) in a pure weight loss population, could show over 30% weight loss—potentially approaching bariatric surgery levels without surgery.
Side Effects: The Trade-off
Higher efficacy appears to come with somewhat higher discontinuation rates:
| Group | Discontinuation Due to Adverse Events |
|---|---|
| Retatrutide 12mg | 18.2% |
| Retatrutide 9mg | 12.2% |
| Placebo | 4.0% |
The most common side effects are consistent with other GLP-1 drugs:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Dysesthesia (abnormal sensations)
JPMorgan analysts noted that tolerability data is "somewhat worse vs Zepbound." The 18% discontinuation rate on the highest dose is higher than seen with tirzepatide (~6-10% in SURMOUNT trials). This may limit who can tolerate the full dose.
The Cardiometabolic Picture
Beyond weight loss, TRIUMPH-4 showed improvements in cardiovascular risk markers:
- Reduced non-HDL cholesterol
- Lower systolic blood pressure
- Reduced inflammation markers
However, we don't yet have cardiovascular outcomes data (like the SELECT trial provided for semaglutide). Those studies are ongoing.
Timeline: When Could It Be Available?
- 2023: TRIUMPH program began enrollment (5,800+ participants)
- December 2025: First Phase 3 results (TRIUMPH-4)
- 2026: Seven additional Phase 3 trials expected to report
- 2027: Potential FDA approval (GlobalData estimate)
- 2031: Projected sales of $15.6 billion (GlobalData forecast)
Who Might Benefit Most?
Given the higher efficacy but also higher discontinuation rates, retatrutide may be best suited for:
- Patients with severe obesity who need maximum weight loss
- Those who haven't achieved goals on semaglutide or tirzepatide
- Patients with obesity-related complications like knee osteoarthritis or sleep apnea
- Those who might otherwise need bariatric surgery
What We Don't Know Yet
- Long-term safety: Will the glucagon component cause any unexpected issues over years?
- Cardiovascular outcomes: Does the weight loss translate to fewer heart attacks/strokes?
- Muscle preservation: Does higher weight loss mean more muscle loss?
- Optimal dosing: Would lower "maintenance" doses (4mg) work after reaching goal weight?
- Pricing: Will it be more expensive than current options?
Retatrutide represents the next frontier in obesity treatment—a triple hormone agonist showing the highest weight loss ever recorded in Phase 3 trials (28.7%). The addition of glucagon receptor activation appears to boost efficacy significantly beyond dual agonists like tirzepatide.
However, higher efficacy comes with somewhat higher discontinuation rates (~18% vs ~6-10% for tirzepatide), suggesting tolerability may limit who can take the full dose.
Key numbers:
- 28.7% average weight loss at 68 weeks
- 71.2 lbs average weight loss
- ~40% of patients lost ≥30% body weight
- 75.8% reduction in knee pain
Status: Not yet FDA-approved. First Phase 3 trial successful. Seven additional Phase 3 trials reporting in 2026. Potential FDA approval in 2027.
Sources
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial." Press release. December 11, 2025.
- CNBC. "Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial." December 11, 2025.
- BioSpace. "Lilly's Retatrutide Scores Triple Trial Triumph With 26% Weight Loss." December 2025.
- Clinical Trials Arena. "Lilly's triple G agonist boasts 28.7% weight loss in Phase III trial." December 2025.
- Pharmaceutical Journal. "Investigational weight-loss drug trial shows average reduced body weight of 30%." December 2025.
- Giblin K, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." PubMed. October 2025.
Currently Available Options
While retatrutide isn't yet available, explore currently approved GLP-1 medications.
Compare Providers →